ImmunityBio Inc (NASDAQ:IBRX) price closed higher on Monday, April 15, jumping 2.54% above its previous close.
A look at the daily price movement shows that the last close reads $5.11. The company’s 5Y monthly beta was ticking 0.04. Taking into account the 52-week price action we note that the stock hit a 52-week high of $6.93 and 52-week low of $1.25. The stock added 6.72% on its value in the past month.
ImmunityBio Inc, which has a market valuation of $3.53 billion, is expected to release its quarterly earnings report May 09, 2024 – May 13, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give IBRX a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy.
The overview shows that IBRX’s price is at present -6.84% off the SMA20 and 4.23% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 47.13, with weekly volatility standing at 11.89%. The indicator jumps to 11.39% when calculated based on the past 30 days. ImmunityBio Inc (NASDAQ:IBRX)’s beta value is holding at 1.18, while the average true range (ATR) indicator is currently reading 0.58.
An analysis of the ImmunityBio Inc (NASDAQ:IBRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.14 million.
Current records show that the company has 670.87M in outstanding shares. The insiders’ percentage holdings are 79.68% of outstanding shares while the percentage share held by institutions stands at 8.49%. But the 4.38% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
